Healthcare reimbursement may affect SGLT2 inhibitor uptake

0

Adriaan Voors, MD, Professor of Cardiology and Director of the Heart Failure Clinic, University Hospital Groningen, The Netherlands, explains why patients who have received Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2) in hospitals may not be able to take the medication after discharge can continue.

Adriaan Voors, MD, Professor of Cardiology and Director of the Heart Failure Clinic, University Hospital Groningen, The Netherlands, explains why patients with heart failure who were hospitalized with Sodium Glucose Co-Transporter 2 Inhibitors (SGLT2) may not receive treatment can continue medication after discharge.

Transcript

How likely is it that patients will continue using empagliflozin after they are discharged from the hospital?

That can depend on where you live. The intake of SGLT2 inhibitors is now increasing rapidly in my hospital. But of course we also have many options from the health insurance companies and the health system to provide all patients with these drugs. I have to admit that even before empagliflozin was launched in a hospital, there was a tendency to start an SGLT2 inhibitor shortly before discharge.

Not that we did this routinely, but it’s real comfort that you can start it at an earlier stage too, which further increases the chances of it being given. But some countries do not have reimbursements for SGLT2 inhibitors, even in the United States. I’ve heard from some of the coworkers I’ve spoken to that SGLT2 inhibitors aren’t even made available.

So it depends on where you live, including where in the US or Europe you live, whether the reimbursement has been made.


Source link

Share.

Comments are closed.